| The effects of safinamide according to gender in Chinese parkinsonian patients.Sci Rep | PMID 37996493PMC10667246 | 2023-Nov-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.BMC Cancer | PMID 37990162PMC10664363 | 2023-Nov-21 | 0.95 | The record describes a secondary analysis of stem cell collection parameters from two Phase III randomized trials in multiple myeloma. While it meets criteria for oncology, human, randomized, Phase III, and drug intervention, the endpoint studied (PBSC mobilization/collection) is not a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.), and no time-to-event data (Kaplan-Meier, HR) are reported. The report is a secondary analysis of a specific supportive care aspect, not the primary efficacy results. | 待处理 |
| Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.J Clin Oncol | PMID 37478390PMC10666987 | 2023-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.J Clin Oncol | PMID 37647576PMC10666986 | 2023-Nov-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet | PMID 37871608无 PMCID | 2023-Nov-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.J Clin Endocrinol Metab | PMID 37406251PMC10655534 | 2023-Nov-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.N Engl J Med | PMID 37870969无 PMCID | 2023-Nov-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.N Engl J Med | PMID 37870973PMC10698285 | 2023-Nov-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.N Engl J Med | PMID 37966285PMC10794000 | 2023-Nov-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial.Nat Commun | PMID 37973806PMC10654517 | 2023-Nov-16 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants.Trials | PMID 37974280PMC10655478 | 2023-Nov-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.Gut Liver | PMID 36789577PMC10651377 | 2023-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial.Int J Radiat Oncol Biol Phys | PMID 37244626无 PMCID | 2023-Nov-15 | 0.90 | The record describes a Phase III randomized trial with time-to-event efficacy endpoints (OS, DFS, local control), but the intervention is a comparison of radiation therapy techniques (IMRT with simultaneous integrated boost vs. 3D conformal with sequential boost). There is no evidence of a drug-containing intervention, which is a required criterion for eligibility. | 待处理 |
| [Effect of recombinant human thrombin for hemostasis in liver resection: a randomized controlled phase Ⅲ clinical trial].Zhonghua Yi Xue Za Zhi | PMID 37963740无 PMCID | 2023-Nov-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.Clin Infect Dis | PMID 37335963PMC10640691 | 2023-Nov-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 37858323无 PMCID | 2023-Nov-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.J Clin Oncol | PMID 37656948无 PMCID | 2023-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.J Clin Oncol | PMID 37748109PMC10642895 | 2023-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.BMJ Open | PMID 37945292PMC10649701 | 2023-Nov-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.J Natl Cancer Inst | PMID 37184928PMC10637036 | 2023-Nov-08 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.Sleep | PMID 37246913PMC10636255 | 2023-Nov-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.JAMA | PMID 37786396PMC10548360 | 2023-Nov-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.J Antimicrob Chemother | PMID 37700689PMC11157139 | 2023-Nov-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).BMC Cancer | PMID 37932681PMC10626703 | 2023-Nov-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.Lancet | PMID 37778358无 PMCID | 2023-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.Lancet | PMID 37863084无 PMCID | 2023-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).J Infect Dis | PMID 37466213PMC10629708 | 2023-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.Vaccine | PMID 37827966无 PMCID | 2023-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reduced Use of Antibiotics and Nasal Decongestants During Treatment with a Mouthwash Containing Delmopinol.Oral Health Prev Dent | PMID 37916545PMC11619836 | 2023-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravenous immunoglobulin for chronic residual peripheral neuropathy in microscopic polyangiitis: A multicentre randomised double-blind trial.Mod Rheumatol | PMID 36346309无 PMCID | 2023-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.J Atheroscler Thromb | PMID 36908150PMC10627746 | 2023-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.Crit Care Med | PMID 37294139无 PMCID | 2023-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perfusate Proteomes Provide Biological Insight Into Oxygenated Versus Standard Hypothermic Machine Perfusion in Kidney Transplantation.Ann Surg | PMID 37503631无 PMCID | 2023-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.Endocr Relat Cancer | PMID 37671811PMC11304032 | 2023-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.Clin J Am Soc Nephrol | PMID 37678222PMC10637459 | 2023-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of fixed-dose combination of Bilastine-Montelukast in adult patients with allergic rhinitis: a phase III, randomized, multi-center, double-blind, active controlled clinical study.J Asthma | PMID 37140964无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis Care Res (Hoboken) | PMID 37165930无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial.J Am Acad Dermatol | PMID 37172733无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.Am Heart J | PMID 37271359无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.Graefes Arch Clin Exp Ophthalmol | PMID 37294433PMC10251323 | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma.Chest | PMID 37385337无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.Clin Exp Rheumatol | PMID 37404160无 PMCID | 2023-Nov | 0.95 | The study is a randomized controlled Phase III trial of a drug (upadacitinib) in humans with original results. However, it is not an oncology study; it investigates psoriatic arthritis, an inflammatory autoimmune condition, not a malignant neoplasm. Furthermore, the primary efficacy endpoints are categorical/improvement scores (e.g., ACR20/50/70, minimal disease activity, PASI), not time-to-event endpoints like OS, PFS, or DFS. Therefore, it does not meet the required criteria for inclusion in this oncology Kaplan-Meier digitization cohort. | 待处理 |
| Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.J Eur Acad Dermatol Venereol | PMID 37432045无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).Ann Surg Oncol | PMID 37450093无 PMCID | 2023-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium.Pediatr Blood Cancer | PMID 37461125无 PMCID | 2023-Nov | 0.85 | The record is from a phase III randomized trial in human oncology but reports only health-related quality-of-life outcomes, not the specified survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for inclusion. | 待处理 |
| Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.J Hepatol | PMID 37479139无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.J Hepatol | PMID 37517454无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of a novel mini-oral sulfate tablet and the conventional oral sulfate tablet in bowel preparation for colonoscopy: a prospective, randomized, investigator-blinded, multicenter, non-inferior, phase 3 trial.J Gastroenterol | PMID 37542674无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.Gastric Cancer | PMID 37548812PMC10640480 | 2023-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.J Allergy Clin Immunol Pract | PMID 37586475无 PMCID | 2023-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |